Understanding these helps you recognise what is expected and when to seek advice
doi:10.1530/erc-23-0319 European Medicines Agency
Second, the off-label adoption pattern that the longevity reframing will inevitably accelerate is going to produce the next wave of monitoring, dosing, and selection problems, patients without obesity or diabetes do not have the diagnostic anchors (BMI, A1c, insulin resistance markers) that frame the on-label conversation, and the clinical infrastructure for managing GLP-1 therapy in metabolically healthy users is, charitably described, thin
The reaction of anti-mouse IgG that should have been non-specific, nearly resembled the specific conjugated anti-rat IgG antibody detection for the rat serum IgG
Melatonin and inflammation-story of a double-edged blade
These variations are all natural results of how your unique body has healed from a major abdominal surgery